Systemic Idiopathic Juvenile Arthritis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Systemic Idiopathic Juvenile Arthritis – Pipeline Review, H1 2017’, provides an overview of the Systemic Idiopathic Juvenile Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis

– The report reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Systemic Idiopathic Juvenile Arthritis therapeutics and enlists all their major and minor projects

– The report assesses Systemic Idiopathic Juvenile Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alteogen Inc

Bristol-Myers Squibb Company

Johnson & Johnson

Livzon Pharmaceutical Group Inc

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Novartis AG

Oncobiologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Systemic Idiopathic Juvenile Arthritis Overview

Systemic Idiopathic Juvenile Arthritis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Systemic Idiopathic Juvenile Arthritis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Systemic Idiopathic Juvenile Arthritis Companies Involved in Therapeutics Development

Alteogen Inc

Bristol-Myers Squibb Company

Johnson & Johnson

Livzon Pharmaceutical Group Inc

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Novartis AG

Oncobiologics Inc

Systemic Idiopathic Juvenile Arthritis Drug Profiles

abatacept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic Idiopathic Juvenile Arthritis Dormant Projects

Systemic Idiopathic Juvenile Arthritis Discontinued Products

Systemic Idiopathic Juvenile Arthritis Product Development Milestones

Featured News & Press Releases

Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris

May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis

Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials

Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting

Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012

Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Alteogen Inc, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Bristol-Myers Squibb Company, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Johnson & Johnson, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Livzon Pharmaceutical Group Inc, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Mycenax Biotech Inc, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Novartis AG, H1 2017

Systemic Idiopathic Juvenile Arthritis Pipeline by Oncobiologics Inc, H1 2017

Systemic Idiopathic Juvenile Arthritis Dormant Projects, H1 2017

Systemic Idiopathic Juvenile Arthritis Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports